Access in all areas? A round-up of developments in market access and health technology assessment: part 13
Abstract
In this update we cover the US-UK Economic Prosperity Deal announced in December 2025, which includes NICE's first major cost-effectiveness threshold increase in over two decades. We also analyze the latest developments in US pharmaceutical pricing policy, including the second cycle of Inflation Reduction Act drug price negotiations and the implementation of the GENEROUS, GUARD and GLOBE Models for Most-Favored-Nation pricing.
Fields of Study & Subjects
Health Systems
Economic Evaluations
Quality of Life
Pharmaceutical Economics and Policy
Global Health Care Issues
Publication details
- Journal / source
- Journal of Comparative Effectiveness Research
- Publisher
- Becaris Publishing Limited
- Volume
- 15
- Issue
- 4
- Pages
- e260041–e260041
- Publication date
- 23 February 2026
- Language
- EN